Multiply Labs raises $75M to optimize pharmaceutical manufacturing with robots
$75M. Multiply Labs just closed its Series B to scale pharmaceutical manufacturing robots — with AstraZeneca and a prominent medical investor aboard.
Why it matters
A mid-stage funding round for manufacturing automation in pharma, backed by a major drugmaker. Signals enterprise conviction in robotics for production optimization, though the deal lacks AI-specific framing and the article is thin on deployment scale or economics.
The key facts
10 to knowSeries B: $75M
Lead: Patrick Soon-Shiong (medical researcher/investor)
Other backers: AstraZeneca, Teradyne, and more than half a dozen additional investors
Focus: automation equipment for pharmaceutical manufacturing
Announcement date: October 6, 2026
Series B funding: $75M
Lead investor: Patrick Soon-Shiong (medical researcher/investor)
Strategic backers include AstraZeneca and Teradyne
Company focus: automation equipment for pharmaceutical manufacturing
Funding announcement date: October 6, 2026
Go to the source
SiliconAnglesiliconangle.com
Publisher excerpt: Multiply Labs Inc., a startup that develops automation equipment for drugmakers, has raised $75 million in funding. Prominent medical researcher Patrick Soon-Shiong led the deal. Multiply Labs stated in today’s funding announcement that the Series B raise also drew more than a half-dozen other…